- Home
- RCKT vs DAWN Comparison
RCKT vs DAWN Comparison
Compare RCKT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- DAWN
- Stock Information
- Founded
- RCKT 1999
- DAWN 2018
- Country
- RCKT United States
- DAWN United States
- Employees
- RCKT N/A
- DAWN N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- DAWN Health Care
- Exchange
- RCKT Nasdaq
- DAWN Nasdaq
- Market Cap
- RCKT 1.1B
- DAWN 1.2B
- IPO Year
- RCKT N/A
- DAWN 2021
- Fundamental
- Price
- RCKT $10.47
- DAWN $12.43
- Analyst Decision
- RCKT Strong Buy
- DAWN Strong Buy
- Analyst Count
- RCKT 10
- DAWN 7
- Target Price
- RCKT $48.80
- DAWN $36.17
- AVG Volume (30 Days)
- RCKT 1.3M
- DAWN 811.6K
- Earning Date
- RCKT 03-04-2025
- DAWN 02-25-2025
- Dividend Yield
- RCKT N/A
- DAWN N/A
- EPS Growth
- RCKT N/A
- DAWN N/A
- EPS
- RCKT N/A
- DAWN N/A
- Revenue
- RCKT N/A
- DAWN $101,953,000.00
- Revenue This Year
- RCKT N/A
- DAWN N/A
- Revenue Next Year
- RCKT $225,168.40
- DAWN $35.37
- P/E Ratio
- RCKT N/A
- DAWN N/A
- Revenue Growth
- RCKT N/A
- DAWN N/A
- 52 Week Low
- RCKT $9.33
- DAWN $11.13
- 52 Week High
- RCKT $31.47
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- RCKT 45.20
- DAWN 52.15
- Support Level
- RCKT $9.33
- DAWN $11.65
- Resistance Level
- RCKT $11.09
- DAWN $12.54
- Average True Range (ATR)
- RCKT 0.52
- DAWN 0.47
- MACD
- RCKT 0.11
- DAWN 0.02
- Stochastic Oscillator
- RCKT 53.77
- DAWN 80.53
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.